Yufan, Abound Bio to develop CAR T cell therapies

By The Science Advisory Board staff writers

September 16, 2020 -- Yufan Biotechnologies and Abound Bio have signed a multiyear agreement to find antibodies to direct chimeric antigen receptor (CAR) T cells against cancer targets.

The three-year deal covers incorporating antibodies to 10 cancer targets into a HPK1- (hematopoietic progenitor kinase 1) inhibited CAR T-cell platform. HPK1 promotes T-cell exhaustion, which is a strategy that can be used to improve CAR T-cell immunotherapy.

Seattle Genetics, Merck partner on 2 oncology drug programs
Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate. Separately,...
Neogene Therapeutics to develop personalized cell therapies
Neogene Therapeutics is pioneering a new class of fully personalized neoantigen T-cell therapies to treat cancer supported by $110 million in series...
New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that...
Integral Molecular aids with safety testing of COVID-19 antibodies
Integral Molecular is applying its membrane proteome array technology for antibody specificity profiling to accelerate development of SARS-CoV-2 therapeutic...

Copyright © 2020 scienceboard.net

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter